Literature DB >> 23136067

Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.

Yi Sun1, Hua Li.   

Abstract

SAG (Sensitive to Apoptosis Gene), also known as RBX2 (RING box protein 2), ROC2 (Regulator of Cullins 2), or RNF7 (RING Finger Protein 7), was originally cloned in our laboratory as a redox inducible antioxidant protein and later characterized as the second member of the RBX/ROC RING component of the SCF (SKP1-CUL-F-box Proteins) E3 ubiquitin ligase. When acting alone, SAG scavenges oxygen radicals by forming inter- and intra-molecular disulfide bonds, whereas by forming a complex with other components of the SCF E3 ligase, SAG promotes ubiquitination and degradation of a number of protein substrates, including c-JUN, DEPTOR, HIF-1α, IκBα, NF1, NOXA, p27, and procaspase-3, thus regulating various signaling pathways and biological processes. Specifically, SAG protects cells from apoptosis, confers radioresistance, and plays an essential and non-redundant role in mouse embryogenesis and vasculogenesis. Furthermore, stress-inducible SAG is overexpressed in a number of human cancers and SAG overexpression correlates with poor patient prognosis. Finally, SAG transgenic expression in epidermis causes an early stage inhibition, but later stage promotion, of skin tumorigenesis triggered by DMBA/TPA. Given its major role in promoting targeted degradation of tumor suppressive proteins, leading to apoptosis suppression and accelerated tumorigenesis, SAG E3 ligase appears to be an attractive anticancer target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23136067      PMCID: PMC3888511          DOI: 10.1007/s13238-012-2105-7

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  131 in total

1.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Authors:  Hui-Kuan Lin; Zhenbang Chen; Guocan Wang; Caterina Nardella; Szu-Wei Lee; Chia-Hsin Chan; Chan-Hsin Chan; Wei-Lei Yang; Jing Wang; Ainara Egia; Keiichi I Nakayama; Carlos Cordon-Cardo; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation.

Authors:  Mingjia Tan; Yongchao Zhao; Sun-Jung Kim; Margaret Liu; Lijun Jia; Thomas L Saunders; Yuan Zhu; Yi Sun
Journal:  Dev Cell       Date:  2011-11-23       Impact factor: 12.270

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

6.  Regulation of nitric oxide-induced apoptosis by sensitive to apoptosis gene protein.

Authors:  Eun Sun Yang; Jeen-Woo Park
Journal:  Free Radic Res       Date:  2006-03

7.  Human sensitive to apoptosis gene protein inhibits peroxynitrite-induced DNA damage.

Authors:  Sun Yee Kim; Jin Hyup Lee; Eun Sun Yang; In Sup Kil; Jeen-Woo Park
Journal:  Biochem Biophys Res Commun       Date:  2003-02-14       Impact factor: 3.575

8.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 9.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206

Review 10.  Stimulation of angiogenesis by Ras proteins.

Authors:  Onno Kranenburg; Martijn F B G Gebbink; Emile E Voest
Journal:  Biochim Biophys Acta       Date:  2004-03-04
View more
  33 in total

Review 1.  Unlocking mammalian regeneration through hypoxia inducible factor one alpha signaling.

Authors:  Kelsey G DeFrates; Daniela Franco; Ellen Heber-Katz; Phillip B Messersmith
Journal:  Biomaterials       Date:  2021-01-09       Impact factor: 12.479

Review 2.  Ubiquitination involved enzymes and cancer.

Authors:  Mei-juan Zhou; Fang-zhi Chen; Han-chun Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 3.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Authors:  Yongchao Zhao; Meredith A Morgan; Yi Sun
Journal:  Antioxid Redox Signal       Date:  2014-02-20       Impact factor: 8.401

Review 4.  Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications.

Authors:  Samantha F Friend; Francina Deason-Towne; Lisa K Peterson; Allison J Berger; Leonard L Dragone
Journal:  Am J Clin Exp Immunol       Date:  2014-12-05

5.  NEDD8-conjugating enzyme E2 UBE2F confers radiation resistance by protecting lung cancer cells from apoptosis.

Authors:  Lisha Zhou; Changsheng Dong; Zhuoming Xu; Xinran Wang; Luyi Zhang; Siyuan Chen; Jiahao Chen; Yingying Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2021-11-15       Impact factor: 3.066

6.  Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Authors:  Hua Li; Mingjia Tan; Lijun Jia; Dongping Wei; Yongchao Zhao; Guoan Chen; Jie Xu; Lili Zhao; Dafydd Thomas; David G Beer; Yi Sun
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 7.  Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.

Authors:  Chuan-Ming Xie; Wenyi Wei; Yi Sun
Journal:  J Genet Genomics       Date:  2013-02-10       Impact factor: 4.275

8.  Identification of RING-box 2 as a potential target for combating colorectal cancer growth and metastasis.

Authors:  Xiao-Yu Wu; Jian Fang; Zhao-Jin Wang; Che Chen; Jia-Yun Liu; Guan-Nan Wu; Xue-Quan Yao; Fu-Kun Liu; Xin Zhou
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 9.  A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811).

Authors:  Hirokazu Shoji; Daisuke Takahari; Hiroki Hara; Kengo Nagashima; Jun Adachi; Narikazu Boku
Journal:  Future Sci OA       Date:  2021-05-28

Review 10.  Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases.

Authors:  Weihua Zhou; Wenyi Wei; Yi Sun
Journal:  Cell Res       Date:  2013-03-26       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.